Armistice Capital portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Armistice Capital reported a $3.6 bn portfolio of 322 companies (323 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are MDGL, SUPN, CYTK. During the quarter it opened Waters and exited Avanos Medical and Medline.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Armistice Capital has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/ACalidi Biotherapeutics5 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13GGeneration Income PropertiesGIPR10 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Plus 42 more, in its EDGAR filings.
What changed this quarter
385 positions with a change (166 new, 66 added to, 64 trimmed, 89 sold); also, 2 entered through an IPO, 7 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Travere Therapeutics−68%fewer sharesReduced4.8% → 2.5%
- PTC Therapeutics−48%fewer sharesReduced4.7% → 2.4%
- Immunovant−51%fewer sharesReduced2.9% → 1.9%
- Cytokinetics+57%more sharesIncreased1.7% → 2.8%
- Indivior Pharmaceuticals+40%more sharesIncreased3.2% → 3.4%
- Regeneron Pharmaceuticals+149%more sharesIncreased0.9% → 1.5%
- Sanofi+255%more sharesIncreased0.5% → 1.3%
- Neurocrine Biosciences−26%fewer sharesReduced3.1% → 2.5%
- Waters+0.8 ppof portfolioNew— → 0.8%
- Avanos Medical−0.8 ppof portfolioSold out0.9% → —
- Incyte+37%more sharesIncreased2.0% → 2.8%
- Medline−0.7 ppof portfolioSold out0.8% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Madrigal PharmaceuticalsMDGL4.3%
- Indivior PharmaceuticalsSUPN3.4%
- CytokineticsCYTK2.8%
- IncyteINCY2.8%
- Neurocrine BiosciencesNBIX2.5%
- Travere TherapeuticsTVTX2.5%
- Agios PharmaceuticalsAGIO2.5%
- PTC TherapeuticsPTCT2.4%
- UnitedHealth GroupUNH2.1%
- FreshpetFRPT2.1%
- Dyne TherapeuticsDYN1.9%
- Amazon.comAMZN1.9%
- ImmunovantIMVT1.9%
- Rigel PharmaceuticalsRIGL1.8%
- Thermo Fisher ScientificTMO1.7%
Portfolio by sector
- ● Health Care 68%
- ● Information Technology 14%
- ● Consumer Discretionary 8%
- ● Communication Services 3%
- ● Industrials 3%
- ● Consumer Staples 3%
- ● Financials 1%
Declared options (10)
Besides stocks, Armistice Capital declared 2 puts (they gain if the stock falls) and 8 calls (they gain if it rises) with a notional of $4.6 bn. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTState Str Spdr S&P 500 ETF TSPY$2.4 bn
- PUTiShares Russell 2000 ETFIWM$1.7 bn
- CALLCytokineticsCYTK$130M
- CALLAgios PharmaceuticalsAGIO$104M
- CALLPTC TherapeuticsPTCT$53.8M
- CALLImmunovantIMVT$46.2M
- CALLTravere TherapeuticsTVTXnew this quarter$28.4M
- CALLMineralys TherapeuticsMLYSnew this quarter$28.1M
- CALLSentineloneS$27.2M
- CALLGitlabGTLBnew this quarter$8.2M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%; more than 20% is options. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Metropolis CapitalInvestment firm · $3.6 bn
- Voyager Global ManagementInvestment firm · $3.6 bn
- Hyperion Asset ManagementInvestment firm · $3.7 bn
- Leon G CoopermanFamily office · $3.5 bn
- Himalaya Capital ManagementInvestment firm · $3.7 bn
- Navera Investment Management$3.7 bn